PRR34-AS1: A Potential Drug Target and Biomarker (G150381)

Target Name: PRR34-AS1

NCBI ID: G150381

PRR34-AS1

Other Name(s): PRR34 antisense RNA 1

PRR34-AS1: A Potential Drug Target and Biomarker

PrRNA-34 (PRR34) is a non-coding RNA molecule that has been shown to play a critical role in various cellular processes. One of its functions is to act as an antisense RNA, which means it targets specific mRNAs for degradation. PRR34 has been shown to interact with several protein targets, including heat shock protein (HSP) 70 (HSP70), which is a key regulator of gene expression and a potential drug target.

The HSP70 family of proteins is known for their ability to interact with a wide variety of RNA molecules, including PRR34. HSP70s have been shown to play a role in the regulation of gene expression, and they are often involved in the control of protein stability and translation efficiency. PRR34 has been shown to interact with HSP70s and has been proposed as a potential drug target for the treatment of various diseases.

One of the unique features of PRR34 is its ability to act as an antisense RNA. This means that it targets specific mRNAs for degradation, and it can interact with the target mRNAs to either enhance or inhibit their translation into proteins. This mechanism of action is similar to that of traditional small interfering RNA (siRNA), but PRR34 has been shown to have a more specific and targeted approach.

PRR34 has been shown to interact with several different HSP70s, including HSP70A, HSP70B, HSP70C, and HSP70D. These interactions have been shown to play a role in the regulation of various cellular processes, including cell growth, apoptosis, and stress response. PRR34 has also been shown to interact with other non-coding RNAs, including doublecortin (DCL), a protein that plays a role in the regulation of gene expression and has been shown to be involved in various diseases, including cancer.

In addition to its role as an antisense RNA, PRR34 has also been shown to have a role in the regulation of protein stability and translation efficiency. This means that it can interact with the target mRNAs to either enhance or inhibit their translation into proteins, and this mechanism of action is similar to that of traditional small interfering RNA.

The potential drug target status of PRR34 is supported by several different studies. First, there is evidence to suggest that PRR34 can be inhibited by small interfering RNA, which suggests that it may be a good candidate for a drug that inhibits its translation into proteins. Second, there is evidence to suggest that PRR34 can interact with HSP70s, which are known to be involved in the regulation of protein stability and translation efficiency. This suggests that PRR34 may be a good candidate for a drug that targets the HSP70 system.

Finally, there is evidence to suggest that PRR34 may be involved in the regulation of cellular processes that are associated with disease. For example, PRR34 has been shown to play a role in the regulation of cell apoptosis, which is associated with a number of diseases, including cancer. This suggests that PRR34 may be a good candidate for a drug that targets cell apoptosis.

In conclusion, PRR34 is a non-coding RNA molecule that has been shown to play a critical role in various cellular processes. Its ability to act as an antisense RNA and its interactions with the HSP70 system suggest that it may be a potential drug target for the treatment of various diseases. Further research is needed to fully understand the role of PRR34 in cellular processes and to determine its potential as a drug.

Protein Name: PRR34 Antisense RNA 1

The "PRR34-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRR34-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets